CD274 and hepatocellular carcinoma: The most effective US Food and Drug Administration (FDA)-approved treatment for advanced nonresectable HCC is a combination of anti-PD-L1 (atezolizumab) and anti-VEGF (bevacizumab) antibodies, providing an overall response rate of 27% [3,4].